Medasense
Medasense offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication.
- Company typePrivate
- Founded2008
- HeadquartersRamat Gan, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medasense does
Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication Medasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and a proprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market. The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing. Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel.
Medasense firmographics
Firmographics- Name
- Medasense
- Legal name
- Medasense Biometrics Ltd.
- Website
- https://www.medasense.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medasense offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication.
- Ownership category
- akta.pro rank
Medasense industry classification
Industry- Product category
- Nociception Monitoring Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous) (HLAHACAA)
Keywords
Where Medasense is headquartered
LocationHeadquarters
- HQ city
- Ramat Gan
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Medasense business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- PMD-200 Hardware Sales: Sale of PMD-200 patient monitoring devices with NOL technology to hospitals and healthcare facilities. The device is a capital medical equipment purchase with associated consumables for continuous use.
- Distribution Partnerships: Revenue generated through distribution partnerships where partners resell and distribute Medasense products in their respective territories (e.g., Medtronic Israel distribution agreement).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Enterprise Hospital Procurement - Quote-based pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Medasense product offering
Product offeringCore offering
Medasense develops and sells the PMD-200 patient monitor for continuous, real-time measurement of nociception during surgery and critical care. The system uses a finger-probe sensor and proprietary machine-learning algorithms to translate multiple physiological signals into an NOL Index that clinicians use to personalize analgesic dosing.
Product overview
Medasense offers a unified product portfolio centered on its proprietary NOL (Nociception Level Index) AI technology for objective pain monitoring. The core offering is the PMD-200 patient monitor, which provides real-time nociception quantification during surgery and critical care. The pipeline includes NOLedge, which aims to expand AI capabilities into pain prediction, stratification, and prevention across broader care settings. The company also develops an NOL OEM module for integration into partner monitoring platforms.
Differentiator
Problem solved
Functional benefit
Brands
- PMD-200™: Flagship pain response (nociception) monitoring system with NOL technology for use during general anesthesia and in critical care settings.
- NOLedge™
- NOL® Index
Products and services
- PMD-200™ A flagship patient monitor that uses a finger-probe sensor and proprietary AI algorithms to continuously display the NOL (Nociception Level Index) and quantify a patient's nociception during surgery and critical care, enabling clinicians to personalize analgesic dosing.
Quantifiable outcome
- 33% reduction in reported postoperative pain scores in PACU
- +6 more outcomes
Companies that use Medasense
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles3 records
Medasense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
Medasense partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, key and minor.
- Philips (Capsule Medical Device Information Platform)coreIntegration with Philips Capsule MDIP enables streaming of NOL Index and trend data directly to hospital EHR systems including Epic, Oracle/Cerner, MEDITECH and others. Provides automated EMR documentation, clinical surveillance, and analytics capabilities.
- Jefferson Health / Thomas Jefferson UniversitykeyClinical trial collaboration as part of Israel-U.S. HealthTech Pilot Program to study NOL technology during spine surgery procedures at Jefferson's medical center in Philadelphia. Jefferson performs approximately 3,000 spine surgeries annually. Study aims to generate real-world clinical evidence and health economic data for U.S. market entry.
- Blink Device CompanykeyJoint grant awarded by BIRD Foundation for development of personalized anesthesia platform incorporating NOL Nociception Monitoring. Grant accelerates development of NOL OEM module for rapid scalability and collaboration with global strategic partners.
- Medtronic IsraelcoreMedtronic Israel partnership for distribution of NOL Nociception Monitoring technology. Medtronic serves as a strategic distribution partner handling sales and distribution of Medasense products in Israel market.
- MindrayminorCommercial partner displaying Medasense logo on website partner section, indicating distribution or integration relationship.
- Nihon KohdenminorCommercial partner displaying Medasense logo on website partner section, indicating distribution or integration relationship.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Medasense competitors and assessment
Company assessmentDirect peers
- MDoloris Medical Systems: French medical device company that markets the ANI (Analgesia Nociception Index) monitor — the most direct competitor to Medasense's NOL technology for objective intra-operative nociception monitoring. Both target anesthesiologists with AI-derived indices for personalizing analgesic dosing.
- Quantium Medical: Spanish developer of the qCON and qNOX nociception/antinociception monitoring indices. Competes head-to-head with Medasense's NOL in the same anesthesiology use case of guiding opioid and analgesic titration during surgery.
Broad incumbents
- Masimo: Global patient monitoring leader whose SedLine EEG-based anesthesia monitoring and Surgical Pleth Index (SPI) overlap with Medasense's OR pain-monitoring niche. Masimo's installed base at U.S. hospitals and broad multiparameter platform make it the most likely large incumbent to compete for the same anesthesia-workflow slot.
- Dräger: Leading anesthesia and patient monitoring vendor whose Perseus and Zeus anesthesia workstations include analgesia-monitoring adjuncts. PMD-200 attaches to Dräger-equipped ORs, positioning Dräger as both an integration partner and a potential competitor if it bundles its own nociception feature.
- GE Healthcare: Major patient monitoring and anesthesia (Carestation) platform provider. Its installed base in U.S. ORs is the same point of attachment for Medasense, and its hemodynamic monitoring roadmap is the most likely incumbent vector for in-platform nociception features.
- Philips: Both an integration partner (via Capsule MDIP streaming NOL data to hospital EHRs) and a broad patient-monitoring incumbent. Philips's IntelliVue and Capsule footprint make it a powerful distribution ally and a natural competitive threat if it integrates its own analgesia index.
- Mindray: Global patient monitoring and anesthesia vendor listed as a Medasense distribution partner. Mindray's broad OR monitor portfolio and competitive pricing in emerging markets make it both a channel ally and a future bundling competitor.
- Nihon Kohden: Japanese patient monitoring leader with significant U.S. hospital presence and listed as a Medasense distribution partner. Its anesthesia and vital signs monitors are direct attachment points for PMD-200.
- Medtronic: Largest medical device franchise globally, currently distributing NOL in Israel through its local affiliate. Medtronic's portfolio breadth, hospital relationships, and investor arm (Baxter Ventures participated in Medasense's Series C) position it as the most strategic large incumbent — both as a near-term partner and a long-term acquirer/competitor.
- Edwards Lifesciences: Hemodynamic monitoring leader (HemoSphere, FloTrac) competing for the same anesthesia/OR monitoring budget. While Edwards focuses on hemodynamic rather than nociception indices, its premium pricing model and KOL relationships make it a comparable high-value, evidence-driven OR monitoring franchise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medasense social profiles
Digital presenceMedasense compliance and trust
Trust signalCompliance1 record
Medasense financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medasense leadership team
Management profileNumber of profiles
Profiles2 records
Medasense funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medasense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medasense
What does Medasense do?
Medasense develops and sells the PMD-200 patient monitor for continuous, real-time measurement of nociception during surgery and critical care. The system uses a finger-probe sensor and proprietary machine-learning algorithms to translate multiple physiological signals into an NOL Index that clinicians use to personalize analgesic dosing.
Is Medasense a public or private company?
Medasense is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medasense founded?
Medasense was founded in 2008. It employs 11 to 50 people.
Where is Medasense based?
Medasense is headquartered in Ramat Gan, Israel, in the Middle East region.
How does Medasense make money?
Two revenue lines are on record. PMD-200 Hardware Sales are the primary driver. The others are distribution Partnerships.
Who are Medasense's main competitors?
Direct peers on record are MDoloris Medical Systems and Quantium Medical. Broad incumbents are Masimo, Dräger, GE Healthcare, Philips, Mindray, Nihon Kohden, Medtronic and Edwards Lifesciences.
Does Medasense have an API?
No public API is recorded for Medasense.
What industry is Medasense in?
Medasense's product category is Nociception Monitoring Systems. Its primary akta.pro industry code is HLAHACAA, Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous). Its NAICS code is 334510 and its SIC code is 3845.